We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Cogent Biosciences Inc
4 own
3 watching
Current Price
$15.5
$0.32
(2.11%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,082.8M
52-Week High
18.07
52-Week Low
3.79
Average Volume
0.57M
Dividend Yield
--
P/E Ratio
-6.94029851
Market Capitalization1,082.8M52-Week High18.0752-Week Low3.79Average Volume0.57MDividend Yield--P/E Ratio-6.94029851What does the Cogent Biosciences Inc do?
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Cogent Biosciences Inc make?
News & Events about Cogent Biosciences Inc.
Globe Newswire
2days ago
WALTHAM, Mass. and BOULDER, Colo., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will ...
Globe Newswire
25days ago
Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from Phase 2 APEX trial in AdvSM patients and initial clinical data in 2H23 from Phase 2 SUMMIT trial in NonAdvSM patients Rapidly progress bezuclastinib in 2nd-line Gastrointestinal ...
Globe Newswire
29days ago
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer will present at ...
Globe Newswire
2 months ago
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Cogent Biosciences Inc share price today?
Can Indians buy Cogent Biosciences Inc shares?
How can I buy Cogent Biosciences Inc shares from India?
Can Fractional shares of Cogent Biosciences Inc be purchased?
What are the documents required to start investing in Cogent Biosciences Inc stocks?
What is today’s traded volume of Cogent Biosciences Inc?
What is today’s market capitalisation of Cogent Biosciences Inc?
What is the 52-Week High and Low Range of Cogent Biosciences Inc?
What percentage is Cogent Biosciences Inc down from its 52-Week High?
What percentage is Cogent Biosciences Inc up from its 52-Week Low?
Current Price
$15.5
$0.32
(2.11%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.